Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Remember, you only see each mm's best, or lowest, ask on L2. If the 20+ million ask is with one of the 2 mm's currently at a lower ask than 24, you won't see it until the lower asks are bought or removed. Most people never seem to notice that an mm is never duplicated, or shown more than once, on the bid or ask. Only the mm's themselves, with L3, can see everthing.
21 million on the ask at 24. Someone trying to kill any upward movement.
Aren't most stocks pps forward-looking?
Define "a lot of money".
Hope that continues! The last couple of buys at 05 have been mine, with a partial still active.
Sorry, 06 and 23!
That's assuming NITE has nothing between 05 and 23.
How do you figure 35 million when 190 million have already traded today?
Daré Bioscience, Inc. Announces Proposed Public Offering of Common StockSource: GlobeNewswire Inc.
Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it intends to offer primary shares of its common stock and warrants to purchase shares of its common stock in a public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Roth Capital Partners is acting as sole underwriter for the proposed offering.
The Company intends to use the net proceeds for working capital and general corporate purposes, which include, but are not limited to, advancing its product portfolio, acquiring the rights to new product candidates, and general and administrative expenses.
A shelf registration statement relating to the shares of common stock and warrants to be issued in the proposed offering was filed with the Securities and Exchange Commission (the "SEC") and is effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the preliminary prospectus supplement and accompanying prospectus will be filed with the Securities and Exchange Commission and, when available, may be obtained from Roth Capital Partners, LLC, 888 San Clemente, Newport Beach, CA 92660, (800) 678-9147 or by accessing the SEC's website, www.sec.gov.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. The company is driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. Daré’s lead product candidate, Ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies. The company is headquartered in San Diego. For more information please visit www.darebioscience.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995 regarding matters that are not historical facts, including statements relating to Daré's expectations regarding the completion and terms of the public offering referenced above, anticipated market demands for its products, the safety and effectiveness of its products, market acceptance of Daré's products and the qualifications and expertise of Daré's management team. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation and completion of clinical trials; availability and timing of data from ongoing and future clinical trials and the results of such trials; whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals; claims of infringement and other risks relating to Daré's owned and licensed intellectual property rights, and other factors discussed in the "Risk Factors" section of Daré's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2017. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in Daré's reports to the Securities and Exchange Commission, including Daré's reports on Forms 10-Q, 8-K and 10-K. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. Daré specifically disclaims any obligation to update any forward-looking statements included in this press release.
Media Contact:
Amanda Guisbond
Vice President
Canale Communications
Amanda@canalecomm.com
781-405-8775
Source: Daré Bioscience
Sorry, wrong board.
That's a novice's interpretation of a T- trade!
We'll see tomorrow morning if there's any correlation between the lousy closing half hour and the anticipated PR. No PR or less than stellar PR will tell us that smart money had an inside track not available to us.
Your spelling is just as bad the 2nd time!
Don't think you're taking into account the increase in outstanding shares over the years in the chart.
Don't you have to have some serious computer power for that? Is that an asset they can afford?
How does value of a bitcoin relate to company revenue from storing customer bitcoins in their vault?
Sorry, meant SANP.
Maybe we'll get some SAMP money in here. It's down to 13!
Don't think you want to use your 1 post today.
I think at the very least, today may disprove a correlation of share movement with a rising bitcoin value, which is now $5338. Of course the email problem may have had an influence on that.
12 M sell at 16
It's the same type of mental flaw that a certain political leader has that compels him to beat a dead horse into the ground.
2%?
Tdameritrade won't allow a buy order!
Do you realize you're just seeing each MM's best, or lowest, ask? Saying "thin", while technically possible, is a mis characterization without L3.
You bought 4000 at .021? What happened to the 500k?
If that's the case, we've done well without her and don't have to relinquish 40% of the profits going forward.
Wrong, they "run it like a Nasdaq company", will not be a Nasdaq company, at least not anytime soon.
Anyone on Ihub selling down here? Would be interesting to hear why, considering the generally positive message flow.
Does the typical gap fill just touch on gap price and immediately start quickly rising, or hover at or below the gap for various periods of time?
Any news that reaches outside the Ihub universe!
Thanks, didn't realize that much. Could we all chip in!
Will 9/15 be first widespread official release of financials, rather than just phone calls and social media?
Thanks, some good thoughts.
In trying to understand the functionality of the app, I assume it's tied into the auto software, and can't easily be bypassed by the driver, short of, say, using a second smartphone, or just not accessing the auto' s Bluetooth connection with the first phone.
Well said! And some of those people who complain about traders are also ardent chartists. Those charts hold the history of both long and short term investors, as well as shorters. You can't support one without the others.
But 49% of that.
How does the app prevent misuse, say by the driver using a smartphone not tied to the auto software?
.
The FMS safe driving app does a number of things to keep your attention on the road while you're driving and not on your smart phone. As soon as the FMS app detects that the vehicles wheels are in motion the App automatically shuts down all voice and social media communication ability for safe, distraction-free driving.
The safe driving app by FMS features 3 key components as follows:
-First, the app is automatically enabled as soon as you start driving and automatically replies to any incoming text messages in a way that's similar to an out of office message so the text sender knows you're driving and can't reply right now.
-Second, it silences audio tones for texts, emails, and phone calls.
-Third, it blocks Web browsing, texting and outgoing phone calls—except for emergency 911 calls.
Sorry, didn't know. Why do you think that happened?